When compared with trifluridine/tipiracil (TAS-102), regorafenib was found to be less clinically and cost-effective in 5 studies that compared the standard dose of regorafenib vs TAS-102. TAS-102 combined with bevacizumab was less cost-effective than regorafenib on dose optimization. Serplulimab was also more cost-effective compared with regorafenib in patients who were previously treated for mCRC. Although regorafenib was more cost-effective than best supportive care, it was less cost-effective than other third-line treatments for mCRC. Dose optimization could make regorafenib more cost-effective in the future.

Source: New York Times June 11, 2024 16:23 UTC